AI Article Synopsis
- Parenteral artesunate is the preferred treatment for high parasitemia malaria cases.
- An Italian man treated with intravenous artesunate showed quick improvement in his malaria symptoms.
- However, he later developed severe hemolytic anemia as a side effect, necessitating blood transfusions.
Article Abstract
Parenteral artesunate has become the choice treatment of cases of high parasitemia malaria. We report the case of an Italian man with a high malaria parasitemia who promptly improved with intravenous artenusate, but who developed a delayed severe hemolytic anemia associated with intravenous artesunate treatment, requiring blood trasfusions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543547 | PMC |
| http://dx.doi.org/10.1002/ccr3.9292 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inaccurate communication in health sciences: The case of 'partial artemisinin resistance' for the treatment of malaria.
New Microbes New Infect
December 2024
Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, Amsterdam Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the Netherlands.
Background: Accurate scientific terminology is crucial in health sciences to avoid misinterpretations. The use of 'artemisinin resistance' to describe delayed parasite clearance may be inaccurately equated with full resistance, as is typically the case when 'resistance' is used with other pathogens, leading to potential confusion. In 2018, the World Health Organization (WHO) introduced 'partial artemisinin resistance' to more accurately reflect the delayed parasite clearance observed with artemisinin-based therapies.
View Article and Find Full Text PDFWeekly dihydroartemisinin-piperaquine versus monthly sulfadoxine-pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial.
Lancet Infect Dis
December 2024
Training and Research Unit of Excellence, Blantyre, Malawi; School of Global and Public Health, Kamuzu University of Health Sciences, Blantyre, Malawi.
Background: In many sub-Saharan African countries, it is recommended that children with sickle cell anaemia receive malaria chemoprevention with monthly sulfadoxine-pyrimethamine or daily proguanil as the standard of care. However, the efficacy of these interventions is compromised by high-grade antifolate resistance of Plasmodium falciparum and poor adherence. We aimed to compare the efficacy of weekly dihydroartemisinin-piperaquine and monthly sulfadoxine-pyrimethamine for the prevention of clinical malaria in children with sickle cell anaemia in areas with high-grade sulfadoxine-pyrimethamine resistance of P falciparum in Uganda and Malawi.
View Article and Find Full Text PDFPyrexia of Foreign Origin: Exploring the Impact of Travel History.
Cureus
November 2024
Internal Medicine, Portsmouth Hospitals University, Portsmouth, GBR.
Malaria remains a significant global health challenge, particularly in endemic regions of Africa, with being the most virulent species. This case report details the presentation of a 24-year-old Caucasian woman who collapsed at a train station in the United Kingdom after experiencing a week of fever, malaise, abdominal pain, and gastrointestinal symptoms. At emergency care, she was initially resuscitated with intravenous fluids and antipyretics.
View Article and Find Full Text PDFMalaria burden and associated risk factors among malaria suspected patients attending health facilities in Kaffa zone, Southwest Ethiopia.
Malar J
December 2024
College of Natural Sciences, Department of Biology, Jimma University, Jimma, Ethiopia.
Background: Ethiopia has been progressing very well in controlling malaria in the past few years. However, shortly after the COVID-19 pandemic, an unpredictable malaria resurgence was observed in almost all malaria-endemic areas of the country, although the exact cause of which has not yet been identified. Therefore, this study aimed to investigate malaria burden and associated risk factors in one of the endemic zones of Ethiopia.
View Article and Find Full Text PDFAssessing tafenoquine implementation in Brazil: a qualitative evaluation of perceptions of healthcare providers and Plasmodium vivax patients (QualiTRuST Study).
Malar J
December 2024
Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil.
Background: To eliminate malaria by 2035, Brazil must address Plasmodium vivax. Previously, first-line treatment was chloroquine plus 7-day primaquine (PQ) without glucose-6-phosphate dehydrogenase (G6PD) deficiency testing. In 2021, point-of-care quantitative G6PD testing and single-dose tafenoquine (TQ) were piloted in two municipalities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!